Last reviewed · How we verify
NCT03061552
Inferior Vena Cava Sonography in Hemodialysis Patients and Quality of Life
NA trial testing sonographic measurement of inferior vena cava diameter in Hemodialysis Complication in 20 participants. Completed in 31 March 2022.
31 May 2021
Quick facts
| Lead sponsor | Hadassah Medical Organization |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 September 2019 |
| Primary completion | 31 May 2021 |
| Estimated completion | 31 March 2022 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- sonographic measurement of inferior vena cava diameter
Conditions studied
- Hemodialysis Complication — all drugs for Hemodialysis Complication →
- End Stage Renal Disease — all drugs for End Stage Renal Disease →
Sponsor
Hadassah Medical Organization — full company profile →
Who can join
18 and older, any sex, with Hemodialysis Complication or End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Determination of dry weight in patients with end-stage renal disease treated with hemodialysis is an unmet challenge in clinical nephrology. Current methods are imprecise, and thus many patients are hype- or hypovolemic, and suffer respective consequences such as hypertension, pulmonary congestion, cardiac hypertrophy, chronic dehydration, hypotension and shock. Several techniques have been proposed to asses hydration status in dialysis patient, among them measurement of bioimpedance and biochemical markers. Sonographic measurement of the inferior vena cava diameter (IVCD) is a method under investigation for assessing hydration status. It is available, inexpensive and efficient, yet operator-dependent. In a single-center, blinded and controlled trial it has been shown to improve clinical outcomes in patients receiving hemodialysis. In this study, we aim to assess the applicability and clinical utility of this method in our dialysis units. A crossover design is intended to examine the effect of IVCD measurement on quality of life and rate of hemodynamic adversities as compared with traditional estimation of dry weight.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03061552
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemodialysis Complication
Currently open trials in the same condition.
- NCT07386691 — Comparing Effect of Intradialytic Aerobic Exercise Versus Incentive Spirometer on Fatigue and Sleep Quality Among Hemodi · NA · active not recruiting
- NCT07512895 — The Effect of Progressive Muscle Relaxation Exercises on Depression and Fatigue in Patients Receiving Hemodialysis Treat · NA · recruiting
- NCT07047547 — A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure · NA · recruiting
- NCT06452563 — Amino Acids Supplementation and Exercise Intervention in Hemodialysis Patients · Phase 4 · active not recruiting
- NCT06520631 — Response Of Arteriovenous Fistula Puncture-related Pain To Cryotherapy Application In Haemodialysis Patients · NA · recruiting
Other Hadassah Medical Organization trials
Trials by the same sponsor.
- NCT07430358 — Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence · NA · not yet recruiting
- NCT07429019 — Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind T · NA · not yet recruiting
- NCT07393568 — The Influence of Patient Use of Artificial Intelligence on Doctor-Patient Interaction and Clinical Outcomes in Endometri · not yet recruiting
- NCT07333430 — Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT06762730 — Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Ind · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03061552 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hadassah Medical Organization
- Last refreshed: 20 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03061552.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing